Livzon Pharmaceutical : A Recombinant SARS-Cov-2 Fusion Protein Vaccine (V-01) developed and manufactured by Livzon has shown good protective effects against the Omicron variant in a phase III clinical booster trial

The V-01 vaccine was developed in collaboration with Institute of Biophysics in the Chinese Academy of Sciences and Livzon Mabpharm Inc., a subsidiary of Livzon Pharmaceutical Group. The interim master data analysis has been completed for phase III clinical trial of sequential booster immunization, and critical data have been obtained. It noted that the absolute vaccine efficacy after the V-01 sequential booster was 61.35 percent, which is significantly superior and meets the standards of the World Health Organization.

Phase III clinical trial of V-01 sequential booster is the first phase III clinical trial all over the world to investigate the sequential booster's protection against the Omicron variant. This sequential booster regimen is designed based on two doses of the inactivated vaccine. A strong superiority standard for relative protection is adopted in this clinical trial, which is an international innovation. Meanwhile, the trial also analyzed the virus samples from the infected participants. Among them, 60 specimens were Omicron, while the rest are still undergoing sequencing. The results indicate that the V-01 sequential booster can provide good protection against the Omicron variant.

The results of this clinical trial will help to speed up the marketing process of V-01 vaccine. Against the background of unbalanced vaccine distribution and insufficient supply in the world, the early development and launch of V-01 vaccine will provide more flexibility for domestic and global anti-epidemic scientific vaccination selection, contribute to the global fight against the epidemic, and practice corporate social responsibility.